Appetite Stimulant Market By Pharmacological Class (Progestational Agents, Cannabinoid-Based Therapies, CNS-Active Agents, Corticosteroids); By Drug Type (Megestrol Acetate, Corticosteroids, Cannabinoids, Cyproheptadine, Mirtazapine, Other Appetite Stimulants, Emerging Targeted Therapies); By Indication (Cancer-Associated Anorexia and Cachexia, HIV/AIDS-Associated Wasting, Chronic Disease-Associated Appetite Loss, Geriatric Appetite Decline, Other Applications); By Route of Administration (Oral, Injectable, Other Routes); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By End User (Hospitals and Clinics, Specialty Care Centers, Homecare Settings); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Appetite Stimulant Market Size and How Is the Treatment Landscape Evolving? – (Updated On: 06-Sep-2026)

The Global Appetite Stimulant Market was valued at USD 1.46 billion in 2025 and is projected to reach USD 2.23 billion by 2032, expanding at a CAGR of 6.42% during 2026–2032, according to Strategic Market Research. Appetite stimulants, or orexigenic agents, are medications or compounds used to increase hunger and improve nutritional intake in patients experiencing clinically significant appetite loss, involuntary weight loss, or cachexia associated with chronic disease.

 

The treatment landscape includes a limited number of approved therapies alongside several medications used off-label. Megestrol acetate is FDA-approved for anorexia, cachexia, or significant unexplained weight loss in patients with AIDS. Dronabinol is approved for anorexia associated with weight loss in AIDS and is also used for chemotherapy-related nausea and vomiting. Somatropin is not a direct appetite stimulant but is approved for HIV-associated wasting to increase lean body mass and body weight. Other agents, including mirtazapine, cyproheptadine, and corticosteroids, may be used off-label in selected patients. Treatment selection is influenced by the underlying disease and safety considerations, including sedation, fluid retention, thromboembolic risk, metabolic effects, and mood changes.

 

Demand is closely linked to involuntary weight loss and cachexia rather than a single disease population. U.S. studies estimate clinically significant unintended weight loss in approximately 7%–13% of adults, increasing to 15%–20% among community-dwelling adults aged 65 years and older and substantially higher in institutionalized elderly populations. Disease-associated cachexia is especially important: approximately 50%–80% of patients with advanced cancer may develop cachexia, compared with an estimated 15%–42% of patients with advanced heart failure and 27%–35% of those with COPD.

 

Growth in the appetite stimulant market is therefore being supported by an aging population, increasing chronic-disease burden, cancer-associated cachexia, HIV-related wasting, and greater clinical attention to malnutrition and unintended weight loss. The limited number of specifically approved orexigenic treatments also creates an important unmet need for safer therapies capable of improving appetite, body weight, functional status, and nutritional outcomes.

 

Leading and Fastest-Growing Segments in the Appetite Stimulant Market

 

By Pharmacological Class

Leading Segment – Progestational Agents

Progestational agents represent the leading pharmacological class in the Appetite Stimulant Market, primarily supported by the dominant commercial position of megestrol acetate. Megestrol acetate alone accounted for approximately 38% of the market in 2025, representing USD 554.8 million, and is projected to reach USD 847.4 million by 2032 at a CAGR of approximately 6.23% during 2026–2032. The class maintains its leadership because megestrol acetate has decades of clinical use, an FDA-approved indication for anorexia, cachexia, or significant unexplained weight loss associated with AIDS, broad generic availability, and strong physician familiarity. 

Fastest-Growing Segment – Cannabinoid-Based Therapies

Cannabinoid-based therapies represent the fastest-growing major established pharmacological class, supported principally by dronabinol. The cannabinoid segment accounted for approximately 14% of the market in 2025, valued at USD 204.4 million, and is projected to reach approximately USD 326.5 million by 2032, expanding at a CAGR of around 6.94% during 2026–2032. Growth is supported by the FDA-approved use of dronabinol for anorexia associated with weight loss in adults with AIDS and its additional role in chemotherapy-induced nausea and vomiting. 

 

By Drug Type

Leading Segment: Megestrol Acetate

Megestrol acetate is the leading drug type segment in the appetite stimulant market, accounting for 38% share in 2025, with a market value of USD 554.8 million. The segment is projected to reach USD 847.4 million by 2032, expanding at a CAGR of 6.23% during 2026–2032. Its leading position is supported by decades of clinical experience, FDA-approved use for anorexia, cachexia, or significant unexplained weight loss associated with AIDS, widespread generic availability, and established physician familiarity.

Fastest-Growing Segment: Cannabinoids

Cannabinoids represent the fastest-growing major established drug type segment, expanding at a CAGR of 6.94% during 2026–2032. The segment accounted for 14% market share in 2025, valued at USD 204.4 million, and is expected to reach USD 326.5 million by 2032. Growth is supported by continued clinical use of dronabinol for AIDS-associated anorexia and chemotherapy-induced nausea and vomiting.

 

By Indication

Leading Segment: Cancer-Associated Anorexia and Cachexia

Cancer-associated anorexia and cachexia is the leading indication segment, accounting for 42% share in 2025, representing USD 613.2 million, and is projected to reach USD 966.7 million by 2032 at a CAGR of 6.71%. The segment dominates because cancer patients represent the largest clinical population requiring appetite-supportive interventions, particularly in advanced-stage disease and palliative-care settings.

Fastest-Growing Segment: Geriatric Appetite Decline

Geriatric appetite decline is the fastest-growing major indication segment, expanding at a CAGR of 7.06% during 2026–2032. The segment represented 14% of the market in 2025, valued at USD 204.4 million, and is projected to reach USD 329.5 million by 2032. Growth is associated with aging populations, increasing recognition of frailty-related nutritional challenges, and greater focus on supportive care among older adults.

 

By Route of Administration

Leading Segment: Oral Route

The oral route is the dominant administration segment, accounting for 82% share in 2025, valued at USD 1.20 billion, and is projected to reach USD 1.86 billion by 2032 at a CAGR of 6.44%. Oral formulations remain preferred due to convenience, outpatient suitability, physician familiarity, and strong availability of generic therapies such as megestrol acetate, dronabinol capsules, and other appetite-supportive medications. Established pharmacy distribution networks further strengthen the commercial position of oral products.

Fastest-Growing Segment: Injectable Route

The injectable route is the fastest-growing segment within administration pathways, expanding at a CAGR of 6.27% during 2026–2032. It accounted for 13% of the market in 2025, generating USD 189.8 million, and is expected to reach USD 290.7 million by 2032. Growth is linked to the development of targeted biologic therapies for cachexia, which are more likely to require injectable delivery compared with traditional oral appetite stimulants.

 

By Distribution Channel

Leading Segment: Hospital Pharmacies

Hospital pharmacies lead the distribution channel segment with a 45% share in 2025, representing USD 657.0 million, and are projected to reach USD 1.03 billion by 2032 at a CAGR of 6.55%. Their dominance is supported by the concentration of appetite stimulant use within oncology, palliative care, HIV management, and complex chronic disease treatment pathways. Hospitals also serve as key points for initiating therapies and managing patients requiring multidisciplinary nutritional support.

Fastest-Growing Segment: Hospital Pharmacies

Hospital pharmacies are also the fastest-growing distribution channel, expanding at a CAGR of 6.55% during 2026–2032. Growth is driven by increasing integration of nutritional management into oncology and supportive-care pathways, greater use of specialty medicines, and the potential introduction of targeted cachexia therapies requiring specialist oversight.

 

By End User

Leading Segment: Hospitals and Clinics

Hospitals and clinics represent the leading end-user segment, accounting for 52% share in 2025, valued at USD 759.2 million, and are projected to reach USD 1.19 billion by 2032 at a CAGR of 6.55%. These settings dominate because appetite stimulants are frequently prescribed within oncology departments, palliative-care units, infectious disease services, and chronic disease management programs. Hospitals also play a central role in identifying patients with clinically significant weight loss and initiating supportive treatment.

Fastest-Growing Segment: Specialty Care Centers

Specialty care centers are the fastest-growing end-user segment, expanding at a CAGR of 6.44% during 2026–2032. The segment accounted for 28% market share in 2025, representing USD 408.8 million, and is projected to reach USD 632.8 million by 2032. Growth is supported by the increasing role of oncology-focused centers, palliative-care programs, and specialized nutritional management services that provide targeted care for patients with cachexia and chronic disease-related appetite loss.

 

By Geography

Leading Region: North America

North America leads the global appetite stimulant market, accounting for 39% share in 2025, valued at USD 569.4 million, and is projected to reach USD 872.8 million by 2032 at a CAGR of 6.28%. The region benefits from established oncology infrastructure, strong prescription access, widespread availability of generic therapies, and active development of next-generation cachexia treatments.

Fastest-Growing Region: Asia Pacific

Asia Pacific is the fastest-growing regional market, expanding at a CAGR of 6.95% during 2026–2032. The region represented 22% share in 2025, valued at USD 321.2 million, and is projected to reach USD 513.7 million by 2032. Growth is supported by expanding oncology infrastructure, improving healthcare access, increasing pharmaceutical availability, and rising recognition of disease-associated wasting.

 

Drug Categories and Clinical Innovations Shaping the Appetite Stimulant Market

Megestrol acetate remains the leading drug category, capturing 38% of the market share in 2025, valued at USD 554.8 million, and is expected to reach USD 847.4 million by 2032, growing at a CAGR of 6.23%. As a synthetic progestin hormone, megestrol acetate is widely used to stimulate appetite and promote weight gain in patients suffering from severe weight loss, anorexia, or cachexia, particularly in chronic illnesses, making it a key therapeutic option in supportive care management.

Corticosteroids represented 17% of the market in 2025, valued at USD 248.2 million, and are projected to reach USD 385.2 million by 2032 at a CAGR of 6.49%. Dexamethasone and prednisone remain clinically relevant because they can provide rapid appetite improvement and symptom relief, particularly in advanced cancer and palliative-care settings. However, their role is generally limited to short-term management because prolonged exposure can result in metabolic complications, muscle weakness, and other adverse effects that restrict broader adoption.

Cannabinoids accounted for 14% of the market in 2025, generating USD 204.4 million, and are expected to reach USD 326.5 million by 2032 at a CAGR of 6.94%. Dronabinol represents the primary pharmaceutical cannabinoid option within this category. The therapy is FDA-approved for anorexia associated with weight loss in adults with AIDS and chemotherapy-induced nausea and vomiting when conventional antiemetic treatments are inadequate. Its clinical positioning is differentiated by cannabinoid activity, but controlled-substance classification and varying international regulatory approaches influence prescribing patterns.

Cyproheptadine held a 12% market share in 2025, equivalent to USD 175.2 million, and is projected to reach USD 270.4 million by 2032 at a CAGR of 6.38%. The antihistamine with serotonin-antagonist properties continues to be used selectively for appetite stimulation, particularly in pediatric and specific chronic disease settings. Its lower cost and established availability support continued utilization, although it does not have the same level of dedicated appetite-loss indications as megestrol acetate or dronabinol.

Mirtazapine represented 10% of the market in 2025, valued at USD 146.0 million, and is forecast to reach USD 220.1 million by 2032 at a CAGR of 6.05%. The therapy benefits from extensive clinical familiarity as an antidepressant and its frequent off-label use in patients experiencing appetite loss with depression, anxiety, or insomnia. However, its position within the appetite stimulant market remains supportive rather than disease-specific because clinical evidence for improving cancer cachexia outcomes remains inconsistent.

Other appetite stimulants accounted for 9% of the market in 2025, valued at USD 131.4 million, and are projected to reach USD 180.4 million by 2032 at a CAGR of 4.63%. This category includes additional supportive medicines such as olanzapine and selected corticosteroid formulations. These therapies remain relevant where appetite loss occurs alongside nausea, treatment-related symptoms, or broader supportive-care requirements.

Emerging targeted therapies represent a developing premium segment focused on addressing the biological mechanisms associated with cachexia. Unlike traditional appetite stimulants that mainly improve food intake, newer candidates are being developed to influence pathways associated with inflammation, metabolism, and muscle wasting. This category includes therapies such as ponsegromab, which targets growth differentiation factor-15 (GDF-15), a pathway associated with cancer-associated weight loss.

 

Cancer Cachexia Influencing the Future Direction of the Appetite Stimulant Market

Cancer-associated anorexia and cachexia represented the largest indication segment, accounting for 42% of the appetite stimulant market in 2025, valued at USD 613.2 million, and is projected to reach USD 966.7 million by 2032 at a CAGR of 6.71%. The segment remains commercially important because cancer patients frequently experience appetite loss, involuntary weight reduction, and progressive muscle deterioration that can affect treatment tolerance and functional status.

HIV/AIDS-associated wasting accounted for 18% of the market in 2025, representing USD 262.8 million, and is projected to reach USD 391.1 million by 2032 at a CAGR of 5.84%. This segment remains supported by established FDA-recognized therapies including megestrol acetate and dronabinol. Although effective antiretroviral therapy has reduced the prevalence of severe HIV wasting compared with earlier decades, appetite-supportive treatments continue to have relevance among patients with advanced disease or treatment complications.

Chronic disease-associated appetite loss represented 21% of the market in 2025, valued at USD 306.6 million, and is expected to reach USD 477.1 million by 2032 at a CAGR of 6.52%. This segment includes appetite impairment associated with chronic respiratory disease, kidney disease, neurological disorders, and gastrointestinal conditions. Treatment approaches are generally individualized because appetite loss often occurs alongside multiple disease-related factors.

Geriatric appetite decline accounted for 14% of the market in 2025, equivalent to USD 204.4 million, and is projected to reach USD 329.5 million by 2032 at a CAGR of 7.06%. Aging populations and increasing focus on nutritional management among older adults support this segment; however, prescribing decisions remain cautious. The American Geriatrics Society recommends avoiding routine use of appetite stimulants in older adults unless clinical benefits outweigh risks because improvements in weight do not consistently demonstrate improvements in survival or quality of life.

Other applications represented 5% of the market in 2025, valued at USD 73.0 million, and are projected to reach USD 65.6 million by 2032 at a CAGR of -1.50%. This segment includes less-defined appetite loss indications where treatment adoption is becoming increasingly concentrated around clinically established uses.

 

Administration Routes and Care Settings Influencing the Appetite Stimulant Market

The oral route dominated the appetite stimulant market with an 82% share in 2025, representing USD 1.20 billion, and is projected to reach USD 1.86 billion by 2032 at a CAGR of 6.44%. Oral formulations including tablets, capsules, and suspensions remain the preferred delivery method because they are convenient for outpatient care, widely available through generic manufacturers, and familiar to prescribing physicians. Megestrol acetate oral suspension and dronabinol capsules represent important commercial examples within this category.

Injectable formulations accounted for 13% of the market in 2025, valued at USD 189.8 million, and are projected to reach USD 290.7 million by 2032 at a CAGR of 6.27%. Injectable therapies currently represent a smaller category but may gain strategic importance as biologic therapies targeting cachexia mechanisms advance. Future products using injectable administration may compete based on targeted biological activity rather than simple appetite enhancement.

Other administration routes represented 5% of the market in 2025, valued at USD 73.0 million, and are expected to reach USD 76.4 million by 2032 at a CAGR of 0.67%. These include specialized delivery formats with limited current commercial penetration.

Hospital pharmacies represented the largest distribution channel, accounting for 45% of the market in 2025, valued at USD 657.0 million, and are projected to reach USD 1.03 billion by 2032 at a CAGR of 6.55%. Hospitals remain central because many appetite stimulant prescriptions originate from oncology, palliative-care, and complex chronic disease management pathways.

Retail pharmacies accounted for 38% of the market in 2025, representing USD 554.8 million, and are expected to reach USD 837.1 million by 2032 at a CAGR of 6.04%. Retail distribution remains important for long-established oral therapies prescribed in outpatient settings.

Online pharmacies represented 17% of the market in 2025, valued at USD 248.2 million, and are projected to reach USD 363.9 million by 2032 at a CAGR of 5.61%. Digital prescription platforms and home delivery services are supporting access for chronic-care patients, although controlled substances such as dronabinol face additional dispensing restrictions.

 

Appetite Stimulant Market Developing Across Regions and Emerging Therapeutic Opportunities

North America dominated the global appetite stimulant market in 2025, accounting for 39% of the total market share with a valuation of USD 569.4 million. The region is expected to maintain its leadership position, reaching USD 872.8 million by 2032 at a CAGR of 6.28%. This growth is driven by a well-established healthcare infrastructure, comprehensive reimbursement policies, rising demand for prescription-based therapies, and advanced access to innovative appetite stimulant treatments.

Europe accounted for 27% of the global appetite stimulants market in 2025, reaching a valuation of USD 394.2 million, and is projected to grow to USD 594.6 million by 2032 at a CAGR of 6.05%. The region is witnessing steady adoption of appetite stimulants, supported by an aging population, increasing awareness of clinical nutrition, and the expansion of elderly care programs. Growing healthcare investments and the rising demand for nutritional support solutions are further contributing to market growth across Europe.

Asia Pacific emerged as a significant contributor to the appetite stimulant market, accounting for 22% of the global share in 2025, valued at USD 321.2 million. The region is expected to witness the fastest growth, reaching USD 513.7 million by 2032 at a CAGR of 6.95%. This expansion is driven by an aging population, improved healthcare infrastructure, greater access to medical treatments, and the rising prevalence of chronic diseases requiring nutritional and appetite management solutions.

Latin America held a 7% share of the market in 2025, equivalent to USD 102.2 million, and is projected to reach USD 156.1 million by 2032 at a CAGR of 6.24%. The market is supported by improving access to essential medicines, expanding oncology services, and continued use of affordable generic appetite stimulants. Healthcare systems in countries such as Brazil, Mexico, and Argentina continue to prioritize cost-effective therapies, making established oral products such as megestrol acetate more commercially relevant than premium specialty therapies.

The Middle East and Africa represented 5% of the market in 2025, valued at USD 73.0 million, and are projected to reach USD 92.9 million by 2032 at a CAGR of 3.49%. Growth remains influenced by differences in healthcare infrastructure, specialist availability, and access to advanced supportive-care services. Larger healthcare systems in Gulf countries are developing stronger oncology and chronic disease management capabilities, while broader regional adoption remains dependent on affordability, medicine availability, and specialist-led care pathways.

 

Competition Evolving in the Appetite Stimulant Market

Competition in the appetite stimulant market is divided between established generic therapies and emerging specialty medicines targeting cancer cachexia. Mature products compete primarily through clinical familiarity, formulation availability, cost advantages, and physician experience, while newer entrants are expected to compete through differentiated mechanisms, clinical outcomes, and treatment positioning.

Pfizer Inc.

Pfizer has emerged as a leading innovator in the next-generation appetite stimulant and cachexia treatment space through ponsegromab. The therapy represents a differentiated approach because it targets GDF-15 signaling rather than only increasing appetite. The company is evaluating ponsegromab in late-stage clinical development for cancer cachexia, particularly in patients with metastatic pancreatic cancer. Positive Phase II findings regarding weight improvement, appetite, physical activity, and cachexia symptoms have positioned the program as one of the most closely watched developments in the market.

Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical holds a unique position through Adlumiz (anamorelin), which is commercially available in Japan for cancer cachexia. The product portfolio provides the company with direct experience in a dedicated cachexia treatment category. Unlike conventional appetite stimulants, anamorelin activates the ghrelin receptor pathway to improve appetite-related signaling and support body composition changes. The company continues to generate clinical experience through Japanese post-marketing surveillance and ongoing lifecycle management activities.

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals participates in the established appetite stimulant segment through megestrol acetate oral suspension. The company’s portfolio benefits from continued utilization of generic appetite-supportive therapies in oncology and chronic disease settings. Its position reflects the importance of reliable, lower-cost formulations within a market where many healthcare providers continue to prioritize established treatment options.

Ascend Laboratories, LLC

Ascend Laboratories maintains a position in the cannabinoid segment through generic dronabinol capsules. The company provides multiple dosage strengths of dronabinol, supporting use in FDA-recognized indications including AIDS-associated anorexia and chemotherapy-related nausea and vomiting. Its market position is influenced by the established clinical role of cannabinoids as well as controlled-substance dispensing requirements.

Teva Pharmaceuticals

Teva participates in the broader generic appetite stimulant market through pharmaceutical formulations including megestrol acetate. The company’s involvement reflects the fragmented nature of mature appetite stimulant categories, where competition is driven by manufacturing capabilities, pharmacy availability, and generic portfolio breadth.

Upsher-Smith Laboratories

Upsher-Smith contributes to the megestrol acetate segment through oral suspension formulations. The company’s products support continued availability of established appetite stimulant therapies used across outpatient and supportive-care environments.

 

Analyst Commentary: Next-Generation Cachexia Therapies Poised to Redefine Appetite Stimulation

The appetite stimulant market is entering a transition phase where future growth will depend less on traditional appetite-enhancing drugs and more on therapies targeting the biological drivers of weight loss. Existing treatments such as megestrol acetate and corticosteroids will continue supporting routine care due to affordability and clinical familiarity, but their limitations in preventing muscle wasting create opportunities for innovative approaches.

The most promising breakthrough opportunity is expected from targeted biologic therapies focused on cachexia pathways, particularly GDF-15 inhibition technology. Pfizer’s investigational ponsegromab represents one of the most advanced developments in this category, aiming to address appetite suppression, metabolic disruption, and weight loss associated with cancer cachexia rather than only improving food intake. If late-stage studies demonstrate sustained benefits in body weight, physical function, and quality of life, GDF-15 inhibitors could establish a new treatment category within oncology supportive care.

Another important innovation area is precision medicine-based patient selection, where biomarkers such as GDF-15 levels could identify patients most likely to respond to targeted therapies. This approach may improve treatment outcomes while supporting premium pricing models.

The future market may also favor combination therapies that integrate appetite stimulation with muscle preservation. Technologies combining ghrelin pathway activation, anti-inflammatory approaches, and metabolic regulation could provide more comprehensive solutions for cachexia management.

While cannabinoid-based therapies and established oral stimulants will remain relevant, the highest-value market opportunity is likely to shift toward therapies capable of demonstrating disease-modifying benefits. Companies that successfully move beyond appetite improvement toward preserving muscle mass and improving patient function are expected to gain a competitive advantage in the evolving appetite stimulant landscape.

 

Appetite Stimulant Market Research Methodology and Estimation Framework

The appetite stimulant market assessment was developed using primary and secondary research focused on clinically significant appetite loss, involuntary weight loss, cachexia, treatment utilization, drug indications, and underlying disease burden. Secondary research incorporated regulatory information, prescribing and product data, peer-reviewed clinical studies, epidemiological literature, company disclosures, and industry databases. Because appetite loss is a clinical manifestation rather than a single disease entity, the epidemiological assessment was structured around populations most likely to require pharmacological appetite support, including patients with cancer cachexia, HIV/AIDS-associated wasting, chronic heart failure, COPD, age-related weight loss, and other chronic conditions associated with impaired nutritional intake.

Market sizing applied both bottom-up and top-down approaches. The bottom-up analysis considered eligible and treated patient populations, prescription volumes, duration of therapy, average treatment costs, branded and generic utilization, and use of FDA-approved versus off-label therapies. Revenue estimates incorporated megestrol acetate, dronabinol, relevant wasting treatments, and other clinically utilized appetite-enhancing agents according to their applicable treatment populations. The top-down assessment cross-validated these estimates using disease-specific cachexia prevalence, involuntary weight-loss rates, age-related nutritional risk, healthcare utilization, prescribing patterns, and regional access to supportive and palliative care.

Final market estimates were established through triangulation of epidemiological, clinical, regulatory, prescription, and commercial data. Forecasts through 2032 incorporated growth in cancer and chronic-disease populations, population aging, increasing recognition of cachexia and malnutrition, treatment penetration, pricing and generic competition, and potential introduction of newer appetite- or cachexia-directed therapies. Estimates were adjusted for differences in indication eligibility, treatment duration, regional prescribing practices, reimbursement, adverse-effect limitations, and the fact that not every patient with weight loss or cachexia receives pharmacological appetite stimulation.

 

Appetite Stimulant Market Report Coverage Table

Report Attributes	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 1.46 Billion
Revenue Forecast in 2032	USD 2.23 Billion
Overall Growth Rate	CAGR of 6.42% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Pharmacological Class, Drug Type, Indication, Route of Administration, Distribution Channel, End User, and Geography
By Pharmacological Class	Progestational Agents, Cannabinoid-Based Therapies, CNS-Active Agents, Corticosteroids
By Drug Type	Megestrol Acetate, Corticosteroids, Cannabinoids, Cyproheptadine, Mirtazapine, Other Appetite Stimulants, Emerging Targeted Therapies
By Indication	Cancer-Associated Anorexia and Cachexia, HIV/AIDS-Associated Wasting, Chronic Disease-Associated Appetite Loss, Geriatric Appetite Decline, Other Applications
By Route of Administration	Oral Route, Injectable Route, Other Routes
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies,  Online Pharmacies
By End User	Hospitals and Clinics, Specialty Care Centers, Homecare Settings
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	United States, Japan, Brazil, Mexico, and Argentina
Market Drivers	Aging population, increasing chronic-disease burden, cancer-associated cachexia, HIV-related wasting, and greater clinical attention to malnutrition and unintended weight loss
Customization Option	Available upon request